Added Value of Radiotherapy Following Neoadjuvant FOLFIRINOX for Resectable and Borderline Resectable Pancreatic Cancer: A Systematic Review and Meta-Analysis

Autor: Hjalmar J. van Santvoort, Joost J. Nuyttens, Quisette P. Janssen, Hongchao Qi, Johanna W. Wilmink, Roeland F. de Wilde, Casper H.J. van Eijck, Geertjan van Tienhoven, Alice C. Wei, Bas Groot Koerkamp, Marc G. Besselink, Marjolein Y.V. Homs, Isabelle G. Kivits, Jacob L van Dam

Publikováno v: Annals of Surgical Oncology
Annals of surgical oncology, 28(13), 8297-8308. Springer New York
Annals of Surgical Oncology, 28(13), 8297-8308. Springer New York
Janssen, Q P, van Dam, J L, Kivits, I G, Besselink, M G, van Eijck, C H J, Homs, M Y V, Nuyttens, J J M E, Qi, H, van Santvoort, H J, Wei, A C, de Wilde, R F, Wilmink, J W, van Tienhoven, G & Groot Koerkamp, B 2021, ' Added Value of Radiotherapy Following Neoadjuvant FOLFIRINOX for Resectable and Borderline Resectable Pancreatic Cancer : A Systematic Review and Meta-Analysis ', Annals of Surgical Oncology, vol. 28, no. 13, pp. 8297-8308 . https://doi.org/10.1245/s10434-021-10276-8

Background The added value of radiotherapy following neoadjuvant FOLFIRINOX chemotherapy in patients with resectable or borderline resectable pancreatic cancer ((B)RPC) is unclear. The objective of this meta-analysis was to compare outcomes of patien

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::14a2ad33362fa31c69d43ad98769b148
http://europepmc.org/articles/PMC8591030